Comparing two drug treatments for advanced kidney cancer after immunotherapy
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial compares two new treatment options for advanced kidney cancer (clear cell type) that has worsened after immunotherapy. One group gets two oral drugs (vorolanib and everolimus) together; the other gets a standard targeted therapy (sunitinib).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of kidney cancer called clear cell renal cell carcinoma, confirmed by biopsy.
- You must have already tried an immunotherapy drug (like a PD-1 or PD-L1 inhibitor) alone or with a targeted therapy, but it no longer worked.
- You must not have had more than one prior systemic treatment for your kidney cancer, and you must not have used a targeted therapy (TKI) before.
- You must be between 18 and 80 years old, and your doctor expects you to live at least 12 more weeks.
- You must be physically able to care for yourself (KPS score of 70 or higher) and have at least one tumor that can be measured with imaging.
- You must have adequate organ function and, if applicable, avoid pregnancy during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at switching to a different cancer drug (a TKI or a TKI plus immunotherapy) after your first treatment for advanced kidney cancer has stopped working or caused bad side effects. The goal is to see how well these second treatments work in Chinese patients, which could help choose a better option for you.
This trial tests whether adding a cholesterol-lowering drug (atorvastatin) to the standard combination of two cancer drugs (axitinib and toripalimab) can improve outcomes for people with advanced clear cell kidney cancer that cannot be removed by surgery or has spread. The goal is to see if this three-drug approach is safe and effective.
This trial tests a combination of two drugs — voronib and everolimus — for people with clear cell kidney cancer whose previous targeted therapy and immunotherapy have stopped working. The goal is to see if this new combination can help when other treatments have failed.
This trial tests two new drugs, vorolanib and cadonilimab, for people with advanced kidney cancer that hasn't been treated before. The combination aims to shrink tumors and slow down the cancer's growth.
This trial tests a targeted therapy pill, vorolanib, for people with advanced kidney cancer that has clear cell features and has gotten worse after initial treatment. It may offer a new option when standard second-line treatments are not working.
This trial tests a combination of two drugs (tivozanib and nivolumab) for people with advanced kidney cancer that is not clear cell type. It aims to see if this drug pair can shrink or slow the cancer.
Hear when a new Renal Cell Carcinoma (RCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.